SBIR Phase I: A Novel, Non-Toxic, General Purpose Oxygen Activated Disinfectant

SBIR 第一阶段：一种新型、无毒、通用型氧激活消毒剂

• 批准号: 0109519
• 负责人: G. Duncan Hitchens
• 金额: $ 10万
• 依托单位: Lynntech, Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0109519&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Non; Toxic

This Small Business Innovation Research Phase I project seeks to develop a novel potent class of biocides for use in the food and medical industries. Over the last decade, the emergence of pathogenic microbes that resist conventional treatment, such as antibiotics and chemical disinfectants, has caused great concern to officials in the food and medical industries. Each year nearly two million patients contract an infection whilehospitalized. During the last two decades the rate of nosocomial infections per 1,000 patient days has increased 36 percent, while in 1995 nosocomial infections cost 4.5 billion dollars and contributed to more than 88,000 deaths. These "super bugs" have also reeked havoc in the food industry as foodborne disease causes approximately 76 million illnesses, 325,000 hospitalizations, and 5,000 deaths in the United States each year. The novel class of biocides proposed in this project will be generated on-site and on-demand and will contain the beneficial characteristics of ozone and carboxylic acid or alcohol-based disinfectants while eliminating their respective weaknesses. This new armamentarium of biocides will meet the criteria for an ideal disinfectant that can be recommended by public health officials for food and medical uses.The primary commercial applications of this project will be in the food and healthcare industries.

这个小企业创新研究第一阶段项目旨在开发一种新型的强效杀菌剂，用于食品和医疗行业。在过去十年中，出现了抵抗抗生素和化学消毒剂等常规治疗的病原微生物，引起了食品和医疗行业官员的极大关注。每年有近200万患者在住院期间感染。在过去的20年中，每1,000个病人日的医院感染率增加了36%，而在1995年，医院感染花费了45亿美元，造成了88,000多人死亡。这些“超级细菌”也在食品工业中引起了严重破坏，因为食源性疾病每年在美国造成约7600万人患病，325，000人住院治疗和5，000人死亡。该项目中提出的新型杀菌剂将在现场按需生产，并将包含臭氧和羧酸或醇基消毒剂的有益特性，同时消除其各自的弱点。这种新型杀菌剂将符合公共卫生官员推荐的食品和医疗用途理想消毒剂的标准。该项目的主要商业应用将在食品和医疗行业。